Today, the U.S. Food and Drug Administration approved Phesgo—a combination of pertuzumab, trastuzumab, and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive breast cancer. Patients should be selected based on an FDA-approved […]